Articles related to VALVULAR HEART DISEASE (VHD)

DETECT AS trial showed electronic notifications increased AVR rates by 11% overall and 14% in symptomatic patients, while EARLY TAVR analyses confirmed superior outcomes with timely intervention versus surveillance, with biomarkers failing to predict optimal treatment timing.

The bRIGHT study demonstrates that T-TEER using the TriClip system can lead to sustained TR reduction and quality of life improvements in a diverse, real-world population with advanced tricuspid valve disease.

The FDA has recalled Abbott’s HeartMate 3 LVAD after reports of severe complications during implantation, including blood leakage and air entry, which can lead to serious surgical risks.

A 75-year-old man with dyspnea and exertional syncope is diagnosed with aortic stenosis. After an echocardiogram, what’s next?

A faulty control arm makes a new trial for tricuspid valve regurgitation intervention seem positive. But in reality, the results probably aren’t.

When compared with rivaroxaban in a propensity score–matched cohort of 19,894 patients, apixaban was associated with an approximately 50% lower rate of ischemic stroke or systemic embolism and bleeding compared to rivaroxaban.